학술논문
Phase II trial of lazertinib in patients with epidermal growth factor receptor (EGFR) mutation-positive (M plus ), metastatic non-small cell lung cancer (NSCLC) with asymptomatic or mild symptomatic brain metastases after failure of EGFR tyrosine kinase inhibitor (TKI) (KCSG LU20-15)
Document Type
Journal
Author
Source
Subject
Language
English
ISSN
15277755